- Home
- RDCM vs CTNM Comparison
RDCM vs CTNM Comparison
Compare RDCM & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RDCM | CTNM |
|---|---|---|
| Founded | 1985 | 2009 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.0M | 416.1M |
| IPO Year | 1997 | 2024 |
Fundamental Metrics
Financial Performance| Metric | RDCM | CTNM |
|---|---|---|
| Price | $12.62 | $11.96 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $18.00 | ★ $18.60 |
| AVG Volume (30 Days) | 51.4K | ★ 255.0K |
| Earning Date | 02-11-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.57 | N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $68,901,000.00 | N/A |
| Revenue This Year | $18.86 | N/A |
| Revenue Next Year | $11.39 | N/A |
| P/E Ratio | $19.72 | ★ N/A |
| Revenue Growth | ★ 17.27 | N/A |
| 52 Week Low | $9.88 | $3.35 |
| 52 Week High | $15.98 | $13.49 |
Technical Indicators
Market Signals| Indicator | RDCM | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 36.66 | 58.06 |
| Support Level | $12.55 | $8.92 |
| Resistance Level | $13.03 | $11.90 |
| Average True Range (ATR) | 0.34 | 0.92 |
| MACD | -0.05 | 0.15 |
| Stochastic Oscillator | 8.92 | 79.84 |
Price Performance
Historical ComparisonAbout RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.
About CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.